Wojciech Jurczak, MD, PhD, ​​discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase ...

Duke University blood cancer specialist Lindsay Rein, MD, has developed a rare expertise in myeloproliferative neoplasms ...

The changing therapeutic landscape for urticaria, angioedema, and anaphylaxis is evidenced by emerging treatments reported at ...

Suprachoroidal Delivery Develops as Promising Mainstream Procedure for Treating Multiple Macular Diseases -- SCS Microinjector® Provides ...

Remibrutinib results in significant improvement in composite measure of itching and hives after second-generation H1-antihistamine treatment.

Janus kinase (JAK) inhibitors are an important treatment option for people with chronic inflammatory diseases such as ...

World Effectiveness and Safety of Upadacitinib in Crohn’s Disease: A Multi-Centre Study," published in the March 2025 issue ...

The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction ...

Clinical characteristics were associated with different survival outcomes in patients treated with immune checkpoint ...

Researchers have uncovered a promising therapeutic target for adenoid cystic carcinoma (ACC), a rare cancer of the salivary ...

Protein kinase research presents an opportunity to explore molecular targets in the body to treat diseases like cancer and ...